Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects.
about
Use of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-UpSwitch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012-2014Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy.A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected Rwandans.Optimizing the virological success of tenofovir DF/FTC/rilpivirine in HIV-infected naive and virologically suppressed patients through strict clinical and virological selection.Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study.Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen.Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART.Lipid Changes in Virologically Suppressed HIV-Infected Patients Switching from any Antiretroviral Therapy to the Emtricitabine/Rilpivirine/Tenofovir Single Tablet: GeSida Study 8114.British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015
P2860
Q28546894-E635EFA0-E908-4CFB-AFD3-B7DC64064058Q35628276-DF65076D-9522-4899-B56D-14EC645FB19AQ35907952-1FD317B6-C0AF-40C1-A9EE-23DE776314A2Q37305526-F48DF213-08CF-4B71-A57F-6E89BA233200Q38379391-CE96705E-29A1-4B4B-9CC4-6F4F641495FFQ40132756-CB5D78CA-479F-4BE6-9049-D57094E9C46DQ40401616-D83C817C-A7F6-4307-A519-897A024F03B1Q40790663-F1D86F4A-08C8-41D9-A032-62FC77D5AB63Q40799305-A38FE858-6DD2-4073-8AD5-54DF44A6C428Q57180790-BA4A27D0-09C7-4306-81BD-0CCE2D00D2A3
P2860
Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Switching from tenofovir/emtri ...... ssed, HIV-1-infected subjects.
@en
Switching from tenofovir/emtri ...... ssed, HIV-1-infected subjects.
@nl
type
label
Switching from tenofovir/emtri ...... ssed, HIV-1-infected subjects.
@en
Switching from tenofovir/emtri ...... ssed, HIV-1-infected subjects.
@nl
prefLabel
Switching from tenofovir/emtri ...... ssed, HIV-1-infected subjects.
@en
Switching from tenofovir/emtri ...... ssed, HIV-1-infected subjects.
@nl
P2093
P2860
P356
P1476
Switching from tenofovir/emtri ...... ssed, HIV-1-infected subjects.
@en
P2093
A Raveleau
C Allavena
D Boutoille
E André-Garnier
P2860
P304
P356
10.1093/JAC/DKU187
P407
P577
2014-06-06T00:00:00Z